Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://opt-k.ru
Are you over 18 and want to see adult content?
A complete backup of https://boilingsteam.com
Are you over 18 and want to see adult content?
A complete backup of https://miravalresorts.com
Are you over 18 and want to see adult content?
A complete backup of https://madeira.gov.pt
Are you over 18 and want to see adult content?
A complete backup of https://blackandgoldbanneret.com
Are you over 18 and want to see adult content?
A complete backup of https://grupazawiercie.pl
Are you over 18 and want to see adult content?
A complete backup of https://pixonic.com
Are you over 18 and want to see adult content?
A complete backup of https://employmentcrossing.com
Are you over 18 and want to see adult content?
A complete backup of https://jiuyancf.com
Are you over 18 and want to see adult content?
A complete backup of https://coliseumhealthsystem.com
Are you over 18 and want to see adult content?
A complete backup of https://alke.com
Are you over 18 and want to see adult content?
A complete backup of https://canadianonlinepharmacyelite.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of swiftpaycard.com
Are you over 18 and want to see adult content?
A complete backup of camisetasitapemameiapraia.com.br
Are you over 18 and want to see adult content?
A complete backup of etemaaddaily.com
Are you over 18 and want to see adult content?
A complete backup of creative-diagnostics.com
Are you over 18 and want to see adult content?
A complete backup of wavesofhonor.com
Are you over 18 and want to see adult content?
A complete backup of tms-elektronik.com
Are you over 18 and want to see adult content?
A complete backup of zdraveomlazeni.cz
Are you over 18 and want to see adult content?
A complete backup of beautyintensified.com
Are you over 18 and want to see adult content?
Text
DRUG PIPELINE
XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.Approved.
ORAL ELTANEXOR
Oral Eltanexor. Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed EXPANDED ACCESS PROGRAMJOB OPENINGS
Karyopharm Therapeutics Inc. (the “Company”) is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability KARYOPHARM RECEIVES CONDITIONAL MARKETING AUTHORIZATION NEWTON, Mass., March 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. TARGETING NUCLEAR EXPORT IN CANCER XPO1 Inhibition & SINE Technology. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2021 VIRTUAL A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma. Lead Presenter: Yazmin Odia, Miami Cancer Institute, Baptist Health South Florida (BHSF) Abstract Number: TPS2071. Session: Central Nervous System Tumors. Date and Time: Friday, June 4, 2021; 9:00 a.m. ET.DRUG PIPELINE
XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.Approved.
ORAL ELTANEXOR
Oral Eltanexor. Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed EXPANDED ACCESS PROGRAMJOB OPENINGS
Karyopharm Therapeutics Inc. (the “Company”) is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability KARYOPHARM RECEIVES CONDITIONAL MARKETING AUTHORIZATION NEWTON, Mass., March 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study.ABOUT - KARYOPHARM
About. Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as amechanism to treat
EXPANDED ACCESS PROGRAM Karyopharm’s Expanded Access Program. Expanded Access Programs (also known as EAPs) provide access to an investigational clinical product outside of a clinical trial before the drug has been given marketing approval by the country’s regulatory agency. An EAP is sometimes referred to as a “Named Patient Program” or a “Compassionate UseINVESTOR RELATIONS
Investor Center Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.OUR MANAGEMENT TEAM
Senior Vice President, GMSA and Customer Excellence and Operations. Ran Frenkel, RPh. EVP, Chief Development Officer VERDINEXOR – INVESTIGATIONAL, ORAL SELECTIVE INHIBITOR OF Verdinexor (KPT-335) is a novel, oral Selective Inhibitor of Nuclear Export (SINE) compound being evaluated in a variety of viral indications as well as in autoimmune / inflammatory diseases. Additionally, it is being studied for the treatment of canine cancers, including lymphoma. Verdinexor inhibits the nuclear export function ofExportin-1
MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG YOSEF LANDESMAN, PHD Yosef Landesman, PhD Senior Vice President, Research and Translational Medicine. Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA DLBCL (RELAPSED/REFRACTORY SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. Please visit clinicaltrials.gov for more information aboutthis study.
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. TARGETING NUCLEAR EXPORT IN CANCER XPO1 Inhibition & SINE Technology. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2021 VIRTUAL A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma. Lead Presenter: Yazmin Odia, Miami Cancer Institute, Baptist Health South Florida (BHSF) Abstract Number: TPS2071. Session: Central Nervous System Tumors. Date and Time: Friday, June 4, 2021; 9:00 a.m. ET.DRUG PIPELINE
XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.Approved.
ORAL ELTANEXOR
Oral Eltanexor. Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed EXPANDED ACCESS PROGRAMJOB OPENINGS
Karyopharm Therapeutics Inc. (the “Company”) is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability KARYOPHARM RECEIVES CONDITIONAL MARKETING AUTHORIZATION NEWTON, Mass., March 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. TARGETING NUCLEAR EXPORT IN CANCER XPO1 Inhibition & SINE Technology. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2021 VIRTUAL A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma. Lead Presenter: Yazmin Odia, Miami Cancer Institute, Baptist Health South Florida (BHSF) Abstract Number: TPS2071. Session: Central Nervous System Tumors. Date and Time: Friday, June 4, 2021; 9:00 a.m. ET.DRUG PIPELINE
XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.Approved.
ORAL ELTANEXOR
Oral Eltanexor. Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed EXPANDED ACCESS PROGRAMJOB OPENINGS
Karyopharm Therapeutics Inc. (the “Company”) is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability KARYOPHARM RECEIVES CONDITIONAL MARKETING AUTHORIZATION NEWTON, Mass., March 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study.ABOUT - KARYOPHARM
About. Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as amechanism to treat
EXPANDED ACCESS PROGRAM Karyopharm’s Expanded Access Program. Expanded Access Programs (also known as EAPs) provide access to an investigational clinical product outside of a clinical trial before the drug has been given marketing approval by the country’s regulatory agency. An EAP is sometimes referred to as a “Named Patient Program” or a “Compassionate UseINVESTOR RELATIONS
Investor Center Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.OUR MANAGEMENT TEAM
Senior Vice President, GMSA and Customer Excellence and Operations. Ran Frenkel, RPh. EVP, Chief Development Officer VERDINEXOR – INVESTIGATIONAL, ORAL SELECTIVE INHIBITOR OF Verdinexor (KPT-335) is a novel, oral Selective Inhibitor of Nuclear Export (SINE) compound being evaluated in a variety of viral indications as well as in autoimmune / inflammatory diseases. Additionally, it is being studied for the treatment of canine cancers, including lymphoma. Verdinexor inhibits the nuclear export function ofExportin-1
MICHAEL MASON, MBA, CPA Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG YOSEF LANDESMAN, PHD Yosef Landesman, PhD Senior Vice President, Research and Translational Medicine. Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. SHARON SHACHAM, PHD, MBA Dr. Shacham has led our scientific progress since inception. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led thecompany
DIFFUSE LARGE B-CELL LYMPHOMA DLBCL (RELAPSED/REFRACTORY SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. Please visit clinicaltrials.gov for more information aboutthis study.
DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. TARGETING NUCLEAR EXPORT IN CANCER Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization ofmedicines with the
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2021 VIRTUAL A Randomized, Open-label, Phase 3 Study of Low-dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLGMM23, Sealand
ASH 2020 - KARYOPHARM Effect of prior treatment with proteasome inhibitors on the efficacy and safety of once-weekly selinexor, bortezomib, and dexamethasone in comparison with twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis from the BOSTONstudy
GRANTS AND GIVING
Karyopharm is committed to supporting and partnering with the healthcare community to help advance scientific breakthroughs and improve the lives of patients with cancer and other serious diseases.ORAL ELTANEXOR
Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. MICHAEL MASON, MBA, CPA Michael Mason, MBA, CPA Chief Financial Officer. Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company. YOSEF LANDESMAN, PHD Yosef Landesman, PhD Senior Vice President, Research and Translational Medicine. Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. SHARON SHACHAM, PHD, MBA Sharon Shacham, PhD, MBA Co-Founder, Chief Scientific Officer. Dr. Shacham co-founded Karyopharm in 2008 and has served as our Chief Scientific Officer since December 2012. CRC (COMBINATION WITH PEMBROLIZUMAB) AND NSCLC CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027. This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. TARGETING NUCLEAR EXPORT IN CANCER Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization ofmedicines with the
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2021 VIRTUAL A Randomized, Open-label, Phase 3 Study of Low-dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLGMM23, Sealand
ASH 2020 - KARYOPHARM Effect of prior treatment with proteasome inhibitors on the efficacy and safety of once-weekly selinexor, bortezomib, and dexamethasone in comparison with twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis from the BOSTONstudy
GRANTS AND GIVING
Karyopharm is committed to supporting and partnering with the healthcare community to help advance scientific breakthroughs and improve the lives of patients with cancer and other serious diseases.ORAL ELTANEXOR
Eltanexor (KPT-8602) is an investigational second-generation SINE compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. MICHAEL MASON, MBA, CPA Michael Mason, MBA, CPA Chief Financial Officer. Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company. YOSEF LANDESMAN, PHD Yosef Landesman, PhD Senior Vice President, Research and Translational Medicine. Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. SHARON SHACHAM, PHD, MBA Sharon Shacham, PhD, MBA Co-Founder, Chief Scientific Officer. Dr. Shacham co-founded Karyopharm in 2008 and has served as our Chief Scientific Officer since December 2012. CRC (COMBINATION WITH PEMBROLIZUMAB) AND NSCLC CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027. This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. DIFFUSE LARGE B-CELL LYMPHOMA (COMBINATION WITH CHEMO AND Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025. Indication: DLBCL Title: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Drug: selinexor Please visit clinicaltrials.gov for more information about this study. ASH 2020 - KARYOPHARM Effect of prior treatment with proteasome inhibitors on the efficacy and safety of once-weekly selinexor, bortezomib, and dexamethasone in comparison with twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis from the BOSTONstudy
INVESTOR RELATIONS
Investor Center Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.JOB OPENINGS
Karyopharm Therapeutics Inc. (the “Company”) is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability MICHAEL MASON, MBA, CPA Michael Mason, MBA, CPA Chief Financial Officer. Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company. SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM) Christine I Chen MD1, Nizar Bahlis MD2, Cristina Gasparetto MD3, Sascha A Tuchman MD4, Brea C Lipe MD5, Muhamed Baljevic MD6, Rami Kotb MD7, Heather J Sutherland MD PhD8, William I. Bensinger MD9, Michael Sebag MD PhD10, Richard LeBlanc STEPHEN MITCHENER, PHARMD Stephen Mitchener, PharmD Chief Business Officer. Stephen Mitchener joined Karyopharm in December 2020 and is responsible for setting the partnering and business strategy for the development and commercialization of all Karyopharm clinical and commercial programs. VERDINEXOR – INVESTIGATIONAL, ORAL SELECTIVE INHIBITOR OF Verdinexor (KPT-335) is a novel, oral Selective Inhibitor of Nuclear Export (SINE) compound being evaluated for the treatment of canine cancers as well as a potential anti-viral agent in CONSENSUS RECOMMENDATIONS FOR THE CLINICAL MANAGEMENT OF Commentary Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor Joseph Mikhael,1 Kimberly R. Noonan,2 Beth Faiman,3 Charise Gleason,4 Ajay K. Nooka,4 Luciano J. Costa,5 Sundar Jagannath,6 Paul G. Richardson,2 David Siegel,7 Ajai Chari,6 Suzanne Lentzch8 Clinical Lymphoma, Myeloma & Leukemia, Vol. 20, No. 6, 351-7 ª 2020 DIFFUSE LARGE B-CELL LYMPHOMA DLBCL (RELAPSED/REFRACTORY Indication: Diffuse Large B-cell Lymphoma Title: DLBCL/SADAL: A Phase 2b Open-label Study of selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Drug: selinexor SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for OUTCOMES OF TRIPLE CLASS REFRACTORY PENTA-EXPOSED MULTIPLE Outcomes of Triple Class Refractory Penta-Exposed Multiple Myeloma with Conventional Therapy in Real World vs. Selinexor in STORMClinical Trial
We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policyand Terms of Use
Close
Accept
Cookie Settings
*
YOUR PRIVACY
*
STRICTLY NECESSARY COOKIES*
PERFORMANCE COOKIES
*
FUNCTIONAL COOKIES
*
TARGETING COOKIES
*
SOCIAL MEDIA COOKIES*
PRIVACY POLICY
PRIVACY PREFERENCE CENTERActive
Always Active
Save Settings
Allow All
Skip to content
karyopharm-logo Logo for Karyopharm MainMenu
* Contact
* Clinical Trials
* Careers
* Follow Us
Search __
* About Show submenu* Company Overview
* Management Team
* Board of Directors * Scientific Advisory Board* Grants and Giving
* Careers Show submenu* Our Culture
* Benefits
* Job Opportunities
* Technology & ResearchShow submenu
* Overview
* Disease Areas of Focus: Hematologic Malignancies & Solid TumorsShow
submenu
* Multiple Myeloma
* DLBCL
* SINE Technology (Selective Inhibitor of Nuclear Export) * Supporting Medical Research * Publications and Presentations* Products
* Pipeline Show submenu* Overview
* Oral Selinexor
* Oral Eltanexor
* Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274)* Oral Verdinexor
* Expanded Access
* Patient Resources
* Investors Show submenu* Corporate Profile
* Press Releases
* Events and Presentations * Corporate Governance * Financials & Filings* Stock Information
* Analyst Coverage
* Investor FAQs
* Contact Us
Targeting Disease at the Nuclear Pore Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients withcancer.
Learn More
SINE TECHNOLOGY
Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.LEARN MORE
PIPELINE
Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.LEARN MORE
PRESS RELEASES
*
March 12, 2020
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer*
March 9, 2020
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq ListingRule 5635(c)(4)
View All Press Releases RECENT MEDICAL CONFERENCES Conference: American Society of Hematology (ASH) Annual Meeting Location: Orlando, FL, USA Date: December 7 – 10 Click Here for Details on Abstracts to be Presented Featuring Data from Karyopharm Investigational MedicinesCareers
JOIN THE KARYOPHARM TEAM We are currently looking for candidates who share our passion to help others and who operate with a sense of urgency and a dedication toexcellence.
Learn More
Karyopharm, 2020. All Rights Reserved.* Terms of Use
* Privacy Policy
* Site Map
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0